AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05585008 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: two different denture manufacturing technique (heat cure pack and press technique(heat cure acrylic,Acrostone,Egypt)/3d printed dneture(HARZ lab,Russia))
Description: retention for the two groups will be measured at 0,1 and 3months, patient satisfaction will be recorded, and accuracy of the denture base will be measured on the software.
Study NCT05366634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDK-703 or Placebo
Description: Injection
Study NCT05458206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mulligan snag mobilization and diaphragmatic release
Description: The patients will be in the supine position. The therapist makes manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th ). During the patient's inspiration, the therapist will gently pull the points of hand contacts toward the head and slightly laterally. During exhalation, the therapist will deepen hand contact toward the inner coastal margins.~mulligan snag, Apply a passive intervertebral movement in a superior anterior direction along the facet plane. While maintaining this glide as the patient actively moves in any range of physiological movement
Study NCT06114264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal + Resistance Programs
Description: Exercise: will focus on working the all body by performing functional tasks. Behaviour change: An 'idle alert' of the wrist-worn activity prompter will be set to vibrate after 45 min without movement. Participants will be encouraged to take a 1-2 min activity break.~Education: The basic contents will explain to the patient the main mechanism of chronic pain (pain as a protective system, consequences, etc).~The Mindfulness Based Stress Reduction (MBSR) program will strictly follow the protocol developed by Jon Kabat Zinn. Each session will include three activities: the presentation of a topic, moments of dialogue and exploration in group and a Mindfulness practice.~Resistance functional exercises will replicate functional movements, such as standing from a bed, carrying bags, picking up groceries from the ground, etc.
Study NCT06114264 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: No experimental intervention. The group will receive the same multimodal intervention as the experimental group when the experimental period is over.
Study NCT05361681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromagnetic Field Exposure
Description: All participants were exposed to the electromagnetic field of 4-5 different high power charging systems, charging 4-5 different, commercially available full electric cars
Study NCT05433220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice Advisory using Electronic Health Record
Description: Providers caring for patients randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF, notes the patient's current LVEF and current evidence-based medications, and gives access to an order set with recommended evidence- based, guideline-recommended, and FDA- approved therapies for patients with HFrEF. Providers will also have access to a link to best available guideline recommended information regarding treatment of heart failure to allow further education if desired by the provider. The alerts will also clearly state the expected monitoring and follow-up required for prescriptions of these medications.
Study NCT04712968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular exposure to morning daylight
Description: Participants are asked to stay outside in morning daylight for minimum 30 minutes each day before 1 pm for 6 weeks. A specific plan for individual outdoor possibilities for daylight exposure is made (e.g. a walk, a stay in a park or in their garden, a bike trip). Furthermore a detailed instruction to the personal light tracker LYS Button and the matching LYS Insight app is provided. The LYS Insight app gives the user access to real-time insight of light stimulus. Further, the participants receive psycho-education on the connection between exposure to morning daylight and antidepressant effect. All participants in this group receive the intervention as add-on to usual treatment, which may comprise prescribed antidepressants, psychotherapy, including psycho-education and psychiatric care.
Study NCT06297356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stress ball
Description: Stress balls are soft sponges with a diameter of 2-4 cm. The lightest starting level was preferred for the patients. Patients were allowed to take the stress ball in any hand they wanted. They were asked to squeeze and loosen the ball in their palm at 2-3 second intervals.
Study NCT05371964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat
Description: Imetelstat sodium will be administered as intravenous (IV) every 28 days.
Study NCT05371964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered, orally (PO), twice daily (BID) as the standard of care per local prescribing guidelines.
Study NCT06650332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cadonilimab
Description: Cohort 1:10 mg/kg, iv, Q3W, D1; Cohort 2/3:6 mg/kg, iv, Q2W, D1
Study NCT06650332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: loading dose 8 mg/kg, iv, Q3W, D1; maintenance dose 6 mg/kg, iv, Q3W, D1
Study NCT06650332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Oxaliplatin: 130 mg/m\\(\^2\\), IV, D1; Capecitabine: 1000 mg/m\\(\^2\\), oral (PO), twice daily, D1-14.
Study NCT06650332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: 1.5、2.0、2.5mg/kg，IV，D1，Q2W
Study NCT05458206 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mulligan snag mobilization and diaphragmatic release
Description: The patients will be in the supine position. The therapist makes manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th ). During the patient's inspiration, the therapist will gently pull the points of hand contacts toward the head and slightly laterally. During exhalation, the therapist will deepen hand contact toward the inner coastal margins.~mulligan snag, Apply a passive intervertebral movement in a superior anterior direction along the facet plane. While maintaining this glide as the patient actively moves in any range of physiological movement
Study NCT06650332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Oxaliplatin 85 mg/m\\(\^2\\), IV, d1; Leucovorin (folinic acid) 400 mg/m\\(\^2\\), IV, d1; 5-FU 400 mg/m\\(\^2\\), IV, d1, followed by 2400 mg/m\\(\^2\\), continuous intravenous infusion over 46 hours.
Study NCT05392699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human single chain IL-12 mRNA-single dose
Description: human single chain IL-12 mRNA administered as specified in the treatment arm with injection once only
Study NCT05392699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human single chain IL-12 mRNA-multiple dose
Description: human single chain IL-12 mRNA administered as specified in the treatment arm with injection once per week for 3 weeks
Study NCT05558735 — intervention group
Intervention type: OTHER
Intervention: urine collection
Description: urine collection as part of the care and usual follow-up in the context of suspected prostate cancer
Study NCT05558735 — intervention group
Intervention type: OTHER
Intervention: canine detection
Description: urine sample will be placed in a detection cone to be sniffed by 6 trained dogs
Study NCT05288335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Circular cylindrical mirror modulated frame glasses (compact)
Description: Circular cylindrical mirror modulated frame glasses (compact)
Study NCT05288335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Circular cylindrical mirror modulated frame glasses (strong defocus)
Description: Circular cylindrical mirror modulated frame glasses (strong defocus)
Study NCT05288335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single vision frame glasses
Description: single vision frame glasses
Study NCT06038370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-induced cognitive trance
Description: The cognitive trance-based intervention will consist of a two-day workshop in groups of approximately 10 participants, where they will learn how to induce the cognitive trance, with the use of different sound-loops that can induce trance in untrained people in a safe way. After two weeks of home practice, participants will redo a two-day consolidation training. At-home practice is encouraged between sessions.
Study NCT04890691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feel Bright Light
Description: During the first waking hour, the participants will be required to wear the light visor (either therapeutic or placebo light) for 30 minutes/day for 4 weeks.
Study NCT04890691 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Feel Bright Light
Description: During the first waking hour, the participants will be required to wear the light visor (either therapeutic or placebo light) for 30 minutes/day for 4 weeks.
Study NCT04755491 — intervention group
Intervention type: DEVICE
Intervention: Continuous veno-venous hemofiltration
Description: Treatment of KDIGO stage 3 AKI by CVVH, in which renal replacement therapy is applied using a convection technique (ultrafiltration). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVH treatment.
Study NCT04755491 — intervention group
Intervention type: DEVICE
Intervention: Continuous veno-venous hemodialysis
Description: Treatment of KDIGO stage 3 AKI by CVVD, in which renal replacement therapy is applied using a diffusion technique (dialysis). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVD treatment.
Study NCT06332066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Intranasal OT will be performed using a spray containing 24IU (12IU administered to each nostril), sorbitol, benzyl, alcohol glycerol, distilled water. Dosage and administration method was determined by standard OT studies instructions and guidelines. The substance will be prepared immediately after randomization by an external preparation and delivered and stored until administration under required conditions. The nasal spray will be self administered, with nursing staff supervising for proper administration of substance, and for supervision of side effects.
Study NCT06332066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin nasal spray
Description: Intranasal OT will be performed using a spray containing 24IU (12IU administered to each nostril), sorbitol, benzyl, alcohol glycerol, distilled water. Dosage and administration method was determined by standard OT studies instructions and guidelines. The substance will be prepared immediately after randomization by an external preparation and delivered and stored until administration under required conditions. The nasal spray will be self administered, with nursing staff supervising for proper administration of substance, and for supervision of side effects.
Study NCT04755491 — intervention group
Intervention type: DEVICE
Intervention: Continuous veno-venous hemodiafiltration
Description: Treatment of KDIGO stage 3 AKI by CVVHDF, in which renal replacement therapy is applied using a combination of diffusion technique (dialysis) and convection technique (ultrafiltration). Indication, choice of CRRT modality, and CRRT settings are made by the clinician in charge, following international recommendations. The measurement of chloride transfer over 24h is performed during CVVHDF treatment.
Study NCT06391047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan's Squeeze Technique - manual therapy
Description: This technique was introduced by Brian R. Mulligan. In this technique the therapist places thumb along the tender joint margin and applies force centrally. The patient actively flexes knee and therapist progressively enhances force and at end applies overpressure. This force is decreased as knee moves towards extension. This method helps to maintain the meniscus in its normal position and corrects the derangement of meniscus.
Study NCT06391047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: It includes stretching and strengthening exercises of muscles of the knee joint.
Study NCT06391047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: It includes stretching and strengthening exercises of muscles of the knee joint.
Study NCT05081895 — intervention group
Intervention type: DEVICE
Intervention: Electrical Impedance tomography
Description: Patients will be monitored with electrical impedance tomography during routine care with special attention to effects of neuromuscular blockade and postural changes.
Study NCT05081895 — intervention group
Intervention type: OTHER
Intervention: Lung mechanics and gas exchange
Description: Patient lung mechanics and gas exchange will be monitored during routine clinical care, with specific attention to postural changes and use of neuromuscular blockade.
Study NCT05976802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose budesonide rectal foam
Description: Twice a day for 2 weeks, then once a day for 4 weeks
Study NCT05976802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose budesonide rectal foam
Description: Twice a day for 2 weeks, then once a day for 4 weeks
Study NCT05976802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo rectal foam
Description: Twice a day for 2 weeks, then once a day for 4 weeks
Study NCT04915729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenecteplase
Description: tenecteplase
Study NCT04915729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alteplase
Description: alteplase
Study NCT06030414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMN-301
Description: Intranasally administered powder.
Study NCT05672277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS 1
Description: Parasacral TENS will be applied for 30 minutes 3 days a week during 6 weeks.
Study NCT05672277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS 2
Description: Parasacral TENS will be applied for 30 minutes one day a week during 6 weeks.
Study NCT06465160 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MNV-201 (Autologous CD34+ Cells Enriched with allogenic Placenta Derived Mitochondria)
Description: The participant will undergo 5 days of mobilization by G-CSF administration (Neupogen) once a day during 5 days.~On the 5th day, and after receiving the last dose of Neupogen, the participant will undergo Apheresis to collect CD34+ cells.~MNV-201 consists of autologous CD34+ cells enriched with allogeneic placenta derived mitochondria. Autologous CD34+ cells are isolated from the participant's peripheral blood after mobilization by apheresis. Allogeneic mitochondria are isolated under aseptic conditions from healthy donor placenta, cryopreserved and qualified before use.~Each product package will consist of a ready-for-injection sterile infusion bag containing clinical grade MNV-201 product for IV infusion for a single specified (autologous) participant.
Study NCT06006195 — intervention group
Intervention type: OTHER
Intervention: patients with dysphagia symptoms
Description: patients with dysphagia symptoms examined by high resolution impedance manometry
Study NCT06006195 — intervention group
Intervention type: OTHER
Intervention: patients without dysphagia symptoms
Description: patients without dysphagia symptoms examined by high resolution impedance manometry
Study NCT05708495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: posterior ilium mobilization
Description: the therapist will mobilize the innominate on the affected side posteriorly
Study NCT05708495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: strengthening and stretching exercises
Description: the participants will receive strengthening exercises on the hip and knee joint beside that they will receive stretching exercises
Study NCT05708495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: strengthening and stretching exercises
Description: the participants will receive strengthening exercises on the hip and knee joint beside that they will receive stretching exercises
Study NCT04846010 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PurWet
Description: (1) cang zhu (Atractylodis Rhizoma), bai (zhu Atractylodis macrocephalae Rhizoma), dang shen (Codonopsis Radix), huang qi (Astragali Radix), Fu ling (Poria), Zhu ling (polyporus), Ze xie (Alismatis Rhizoma), Yi yi ren (Coicis Semen), gan cao (Glycyrrhizae Radix),
Study NCT04846010 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: FurFat
Description: (2).shan zha (Crataegi Fructus), Jue Ming Zi (Cassiae Semen), He ye (Nelumbinis Folium), Da huang (Rhei Radix et Rhizoma), Ze xie (Alismatis Rhizoma), dan shen ( Salviae miltiorrhizae Radix).
Study NCT05800054 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Support Team
Description: Nutritionists formulate nutritional programs and manage them in a refined manner. On the basis of the patient's natural diet (food and homogenate meal), enteral nutritional preparations or parenteral nutritional supplements are given according to the patient's gastrointestinal obstruction, dietary structure, and food intake. Energy 30-35kcal/kg/d, protein 1.2-1.5g/kg/d. Enteral nutrition administration route: oral or tube feeding or ostomy, oral feeding is preferred; severe obstruction of eating or oral intake cannot meet the target nutrition, choose tube feeding or ostomy. When it is expected that enteral nutrition cannot meet 60% of the target energy requirement for 3 to 5 days, choose parenteral nutrition. The enteral nutritional preparation adopts the whole protein enteral nutritional preparation Nengquan, and/or the tumor nutritional preparation Ruineng, and/or whey protein powder.
Study NCT04846010 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PurApo
Description: (3)Sheng Di Huang (Rehmanniae Radix), Xuan Shen (Scrophulariae Radix), mai men dong (Ophiopogonis Radix), shan zhu yu (Corni Fructus), shan yao (Dioscoreae Rhizoma), sha yuan zi (Astragali complanati Semen), ci ji li (Tribuli Fructus), nu zhen zi (Ligustri lucidi Fructus)
Study NCT04846010 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PurPhl
Description: (4) chen pi (Citri reticulatae Pericarpium), hua ju hong (Citri grandis Exocartium rubrum), zhi shi (Aurantii Fructus immaturu), zhi ban xia (Pinelliae Rhizoma preparatum), zhi tian nan xing (Arisaematis Rhizoma preparatum),sha ren (Amoni Fructus), Gua lou (Trichosanthis Fructus), Chuan bei mu ( Fritillatiae cirrhosae Bulbu), Fu ling ( Poria), Da huang ( Rhei Radix et Rhizoma).
Study NCT04846010 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PurClo
Description: (2) Dan shen (Salviae miltiorrhizae Radix), Yu jin (Curcumae Radix), chi shao (Paeoniae Radix rubra), tao ren (Persicae Semen), hong hua (Carthami Flos)
Study NCT05800054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60-75 mg/m2, d1, at least 2 cycles in parallel with radiotherapy
Study NCT05800054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin 25mg/m2 d1-3, 21-28d/cycle. at least 2 cycles in parallel with radiotherapy
Study NCT04846010 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PurInf
Description: (1) lei gong teng (Tripterygii wilfordii Radix), Huang Qin (Scutellariae Radix), Huang Lian (Coptidis Rhizoma), Huang Bai (Phellodendri Cortex), Zhi Zi (Gardeniae Fructus).
Study NCT04846010 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Smoliv
Description: (2). Vagus never communicates with LES: yu jin (Curcumae Radix), Chai Hu (Bupleuri Radix), chi shao (Paeoniae Radix rubra), Mu Dan Pi (Moutan Cortex), chuan lian zi (Toosendan Fructus), long gu (Fossilia Ossis Mastodi), mu li (Ostreae Concha)
Study NCT05392920 — intervention group
Intervention type: OTHER
Intervention: assessment study
Description: there is no intervention in this study
Study NCT04952610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etripamil NS 70 mg
Description: Etripamil will be administered via the Aptar Pharma Nasal Spray Bidose System.
Study NCT04952610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aptar Pharma Nasal Spray Bidose System
Description: Aptar Pharma Nasal Spray Bidose System will be supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
Study NCT05726409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Participants will use the meal planner function on the mobile application to plan and cook at least 3 meals a week for 12 weeks.
Study NCT06405048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Weibo post screenshot with mock-up Chinese fact-checking extension
Description: The intervention in this survey experiment involves mobile Weibo post screenshots equipped with a mock-up Chinese fact-checking browser extension. All screenshots are based on actual Weibo posts. The fact-checking content is generated by a Large Language Model (LLM), tailored to relevant knowledge and prompts, and subsequently validated by experts. The Weibo posts cover a range of popular topics known to contain misinformation, including infertility, safety, vaccine ingredients, high-risk cervical cancer types, regular check-ups, transmission routes, and others.